Introduction The development of percutaneous therapies during the last decade has revolutionised the treatment of valvular heart diseases. Nevertheless, the impact of these therapies on clinical practice is not equal for all valve diseases. While transcatheter aortic valve implantation (TAVI) has become the preferred therapy for most patients with aortic stenosis12, transcatheter mitral valve implantation (TMVI) therapies have undergone a longer development process.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Dominique
Contact Dominique, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack